Characterizing RA Disease Activity Before Treatment Choice
Seropositivity, erosions, and joint count shape the treatment decision.
- ~70%: RF/anti-CCP positive (of RA patients seropositive)
- <2.6: DAS28 remission (target disease activity score)
- ~30%: Erosive disease (within 2 years untreated)
- <12 wk: Window of opportunity (early treatment benefit)
Why baseline severity matters
Higher severity and seropositivity predict a more aggressive disease course.
Methotrexate as First-Line Oral DMARD Therapy
Methotrexate is slow but remains the anchor drug for most new RA cases.
- 8–12 wk: Onset of effect (typical response window)
- ~46%: ACR20 response (monotherapy trials)
- 10–25 mg: Weekly dose range (oral or subcutaneous)
- Standard: Folate co-therapy (reduces toxicity)
Why methotrexate is first-line
Low cost and long safety record make it the default starting DMARD.
Biologic Agents for Faster, Targeted RA Control
Biologics act faster but cost more and carry infection risk.
- 2–6 wk: Onset of effect (faster than methotrexate)
- ~60–70%: ACR20 response (anti-TNF combination trials)
- Injectable: Route (subcutaneous or infusion)
- High: Annual cost (vs. generic methotrexate)
When biologics are favored
Severe or refractory disease often shifts choice toward biologics.
Prior DMARD Failure Shifts the Probability Balance
Each prior failed DMARD lowers expected methotrexate success.
- −15pp: 1 prior failure (estimated MTX success drop)
- Biologic favored: 2+ failures (guideline consensus)
- Common: Step-up strategy (MTX then biologic add-on)
- Often used: Combination therapy (MTX + biologic together)
Refractory disease pathway
Repeated failures argue for earlier biologic escalation.
Combining Inputs into a Treatment Pathway Suggestion
The simulator blends severity and failure history into one recommendation.
- MTX first: Mild + naive (guideline default)
- Biologic: Severe/refractory (earlier escalation)
- Combination: Intermediate cases (MTX + biologic)
- ~3 months: Reassessment (standard follow-up interval)
Using the recommendation
This is a simplified illustrative model, not clinical guidance.
Placeholder: consult treat-to-target RA guidelines for real decisions.